Molecular Partners Ltd
MOLN
ISIN CH0256379097 / Valor 25637909
Molecular Partners Ltd
UMushroom community rating:
About company
Molecular Partners Ltd is a clinical-stage biopharmaceutical company based in Switzerland, specializing in the development of a novel class of therapeutic proteins known as DARPins (Designed Ankyrin Repeat Proteins). These proteins are engineered to address complex medical conditions, offering potential advantages over traditional antibodies due to their small size, high specificity, and ability to engage multiple targets simultaneously. The company focuses on creating innovative treatments for diseases with significant unmet medical needs, including oncology and infectious diseases. Molecular Partners collaborates with various pharmaceutical companies to advance its pipeline and leverage its proprietary technology platform. Under the leadership of CEO Patrick Amstutz, who co-founded the company in 2004, Molecular Partners has established numerous commercial partnerships and continues to expand its research and development efforts to bring new therapies to market.
Summarized from source with an LLMView SourceSector: TechnologyLatest Results (09.11.2025):
Molecular Partners Ltd reported its Q4 2024 highlights and full year 2024 audited financial results with robust clinical progress and a strong financial foundation. The company emphasized advancements in its clinical pipeline—including updates on MP0712, MP0533, and its Switch-DARPin platform—while maintaining CHF 149 million in cash, cash equivalents, and short-term deposits to support operations well into 2027.
Strong Financial Position
Molecular Partners Ltd ended 2024 with CHF 149 million in cash, cash equivalents, and short-term deposits, underscoring a sound liquidity base that secures the financial runway for its operations and ongoing clinical programs.
Advancements in Clinical Pipeline
The company updated its progress across several programs: the planned IND submission for MP0712 targeting DLL3 is on course for H1 2025 pending regulatory clearance, and early data from the MP0533 Phase 1/2a clinical trial indicates enhanced response rates. Additionally, further preclinical data from the Switch-DARPin programs is expected throughout 2025.
Strategic Partnerships & Future Milestones
Key collaborations were highlighted, notably the expanded strategic partnership with Orano Med, now encompassing up to ten radiotherapy programs. These partnerships, along with upcoming clinical data and regulatory submissions, position Molecular Partners Ltd for pivotal value inflection points in 2025 and beyond.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
159 M
Market cap (USD)
14,736
Daily traded volume (Shares)
4.675 / 4.44
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
